China Animal Husbandry Industry Past Earnings Performance
Past criteria checks 2/6
China Animal Husbandry Industry has been growing earnings at an average annual rate of 7.1%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 6.6% per year. China Animal Husbandry Industry's return on equity is 4.3%, and it has net margins of 6.2%.
Key information
7.1%
Earnings growth rate
6.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 6.6% |
| Return on equity | 4.3% |
| Net Margin | 6.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How China Animal Husbandry Industry makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 5,470 | 339 | 689 | 125 |
| 31 Dec 23 | 5,406 | 403 | 680 | 123 |
| 30 Sep 23 | 5,925 | 547 | 710 | 147 |
| 30 Jun 23 | 5,803 | 562 | 724 | 137 |
| 31 Mar 23 | 5,830 | 556 | 706 | 139 |
| 31 Dec 22 | 5,892 | 550 | 698 | 143 |
| 30 Sep 22 | 5,522 | 450 | 737 | 149 |
| 30 Jun 22 | 5,314 | 454 | 766 | 155 |
| 31 Mar 22 | 5,135 | 486 | 778 | 162 |
| 31 Dec 21 | 5,302 | 514 | 815 | 163 |
| 30 Sep 21 | 5,255 | 400 | 736 | 155 |
| 30 Jun 21 | 5,300 | 385 | 757 | 166 |
| 31 Mar 21 | 5,220 | 452 | 741 | 173 |
| 31 Dec 20 | 4,999 | 420 | 730 | 170 |
| 30 Sep 20 | 4,830 | 463 | 741 | 185 |
| 30 Jun 20 | 4,583 | 439 | 675 | 182 |
| 31 Mar 20 | 4,405 | 291 | 725 | 168 |
| 31 Dec 19 | 4,136 | 249 | 730 | 170 |
| 30 Sep 19 | 4,196 | 349 | 761 | 184 |
| 30 Jun 19 | 4,373 | 386 | 763 | 171 |
| 31 Mar 19 | 4,295 | 379 | 726 | 166 |
| 31 Dec 18 | 4,434 | 416 | 745 | 167 |
| 30 Sep 18 | 4,643 | 475 | 743 | 116 |
| 30 Jun 18 | 4,452 | 478 | 721 | 162 |
| 31 Mar 18 | 4,228 | 450 | 699 | 140 |
| 01 Jan 18 | 4,070 | 400 | 714 | 115 |
| 30 Sep 17 | 3,846 | 383 | 768 | 76 |
| 30 Jun 17 | 3,733 | 315 | 840 | 0 |
| 31 Mar 17 | 3,887 | 328 | 849 | 0 |
| 31 Dec 16 | 3,974 | 334 | 848 | 0 |
| 30 Sep 16 | 3,866 | 260 | 805 | 0 |
| 30 Jun 16 | 3,900 | 268 | 778 | 0 |
| 31 Mar 16 | 3,738 | 249 | 764 | 0 |
| 31 Dec 15 | 4,234 | 276 | 755 | 0 |
| 30 Sep 15 | 4,581 | 284 | 771 | 0 |
| 30 Jun 15 | 4,543 | 279 | 752 | 0 |
| 31 Mar 15 | 4,622 | 291 | 741 | 0 |
| 31 Dec 14 | 4,035 | 290 | 710 | 0 |
| 30 Sep 14 | 3,787 | 217 | 672 | 0 |
| 30 Jun 14 | 3,734 | 210 | 648 | 0 |
| 31 Mar 14 | 3,693 | 217 | 624 | 0 |
| 31 Dec 13 | 3,640 | 236 | 596 | 0 |
| 30 Sep 13 | 3,348 | 242 | 584 | 0 |
| 30 Jun 13 | 3,281 | 253 | 587 | 0 |
Quality Earnings: 600195 has high quality earnings.
Growing Profit Margin: 600195's current net profit margins (6.2%) are lower than last year (9.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600195's earnings have grown by 7.1% per year over the past 5 years.
Accelerating Growth: 600195's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600195 had negative earnings growth (-39.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.9%).
Return on Equity
High ROE: 600195's Return on Equity (4.3%) is considered low.